P2X3 — Drug Target
All drugs that target P2X3 — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 3 pipeline (4)
- BLU-5937 · Bellus Health Inc. - a GSK company · P2X3 receptor antagonist · Pain Management / Neurology
BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons. - RTX-GRT7039 · Grünenthal GmbH · P2X3 receptor antagonist · Pain Management
RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission. - MR308 · Mundipharma Research GmbH & Co KG · P2X3 receptor antagonist · Pain Management
MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons. - 3APS · Bellus Health Inc. - a GSK company · P2X3 receptor antagonist · Respiratory
3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough.
Phase 2 pipeline (1)
- GRT9906 · Grünenthal GmbH · P2X3 receptor antagonist · Pain management
GRT9906 is a selective antagonist of the P2X3 receptor that reduces pain signal transmission in sensory neurons.